Tamoxifen, raloxifen and breast cancer risk reduction

Presented at the AACR 2010’s Meeting, the NCI sponsored STAR (Study of Tamoxifen and Raloxifen) trial confirms the breast cancer development risk reduction in postmenopausal women considered at a higher risk. 19,000 women participated and tamoxifen and raloxifen reduced de incidence of invasive and noninvasive breast cancer. Raloxifen is safer (less side effects) but less effective than tamoxifen. See JNCI Cancer Bulletin: http://ow.ly/1BvRe